343 related articles for article (PubMed ID: 37497748)
1. Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
Higano CS; Cheng HH
Curr Opin Urol; 2023 Sep; 33(5):396-403. PubMed ID: 37497748
[TBL] [Abstract][Full Text] [Related]
2. Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis.
Messina C; Giunta EF; Signori A; Rebuzzi SE; Banna GL; Maniam A; Buti S; Cattrini C; Fornarini G; Bauckneht M; Greystoke A; Plummer R; Oing C; Rescigno P
Eur Urol Oncol; 2024 Apr; 7(2):179-188. PubMed ID: 37574390
[TBL] [Abstract][Full Text] [Related]
3. First-line combination treatment with PARP and androgen receptor-signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States.
McKay RR; Morgans AK; Shore ND; Dunshee C; Devgan G; Agarwal N
Cancer Treat Rev; 2024 May; 126():102726. PubMed ID: 38613872
[TBL] [Abstract][Full Text] [Related]
4. Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
Sayyid RK; Klaassen Z; Berlin A; Roy S; Brandão LR; Bernardino R; Chavarriaga J; Jiang DM; Spratt DE; Fleshner NE; Wallis CJD
BJU Int; 2023 Dec; 132(6):619-630. PubMed ID: 37461140
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis.
Fallah J; Xu J; Weinstock C; Gao X; Heiss BL; Maguire WF; Chang E; Agrawal S; Tang S; Amiri-Kordestani L; Pazdur R; Kluetz PG; Suzman DL
J Clin Oncol; 2024 May; 42(14):1687-1698. PubMed ID: 38484203
[TBL] [Abstract][Full Text] [Related]
6. Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial.
Chi KN; Sandhu S; Smith MR; Attard G; Saad M; Olmos D; Castro E; Roubaud G; Pereira de Santana Gomes AJ; Small EJ; Rathkopf DE; Gurney H; Jung W; Mason GE; Dibaj S; Wu D; Diorio B; Urtishak K; Del Corral A; Francis P; Kim W; Efstathiou E
Ann Oncol; 2023 Sep; 34(9):772-782. PubMed ID: 37399894
[TBL] [Abstract][Full Text] [Related]
7. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.
Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F
Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291
[TBL] [Abstract][Full Text] [Related]
8. PARPing up the right tree; an overview of PARP inhibitors for metastatic castration-resistant prostate cancer.
Slootbeek PHJ; Overbeek JK; Ligtenberg MJL; van Erp NP; Mehra N
Cancer Lett; 2023 Nov; 577():216367. PubMed ID: 37689306
[TBL] [Abstract][Full Text] [Related]
9. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS; Mehra N; Scagliotti GV; Castro E; Dorff T; Stirling A; Stenzl A; Fleming MT; Higano CS; Saad F; Buttigliero C; van Oort IM; Laird AD; Mata M; Chen HC; Healy CG; Czibere A; Fizazi K
Lancet Oncol; 2021 Sep; 22(9):1250-1264. PubMed ID: 34388386
[TBL] [Abstract][Full Text] [Related]
10. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
11. Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence.
Yang J; Xiong X; Zheng W; Liao X; Xu H; Yang L; Wei Q
Curr Oncol; 2023 Dec; 30(12):10311-10324. PubMed ID: 38132385
[TBL] [Abstract][Full Text] [Related]
12. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K; Azad AA; Matsubara N; Carles J; Fay AP; De Giorgi U; Joung JY; Fong PCC; Voog E; Jones RJ; Shore ND; Dunshee C; Zschäbitz S; Oldenburg J; Ye D; Lin X; Healy CG; Di Santo N; Laird AD; Zohren F; Agarwal N
Nat Med; 2024 Jan; 30(1):257-264. PubMed ID: 38049622
[TBL] [Abstract][Full Text] [Related]
13. [Combination therapy with poly(adenosine diphosphate-ribose) polymerase (PARPi) and androgen receptor signaling pathway (ARPi) inhibitors for metastatic castration-resistant prostate cancer].
Grimm MO; Foller S; Leucht K
Urologie; 2023 Dec; 62(12):1269-1280. PubMed ID: 37978072
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.
Olmos D; Lorente D; Alameda D; Cattrini C; Romero-Laorden N; Lozano R; Lopez-Casas PP; Jambrina A; Capone C; Vanden Broecke AM; Trevisan M; Van Sanden S; Jürgens A; Herrera-Imbroda B; Castro E
Ann Oncol; 2024 May; 35(5):458-472. PubMed ID: 38417742
[TBL] [Abstract][Full Text] [Related]
15. US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer.
Heiss BL; Chang E; Gao X; Truong T; Brave MH; Bloomquist E; Shah A; Hamed S; Kraft J; Chiu HJ; Ricks TK; Tilley A; Pierce WF; Tang L; Abukhdeir A; Kalavar S; Philip R; Tang S; Pazdur R; Amiri-Kordestani L; Kluetz PG; Suzman DL
J Clin Oncol; 2024 Mar; ():JCO2302182. PubMed ID: 38452327
[TBL] [Abstract][Full Text] [Related]
16. Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials.
Chao Z; Wang Z; Li L; Jiang Y; Tang Y; Wang Y; Hao X; Zhang C; Guo X; Yu W; Cheng F; Wang Z
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138301
[No Abstract] [Full Text] [Related]
17. Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer.
Adashek JJ; Jain RK; Zhang J
Cells; 2019 Aug; 8(8):. PubMed ID: 31404966
[TBL] [Abstract][Full Text] [Related]
18. A Novel Use of Olaparib for the Treatment of Metastatic Castration-Recurrent Prostate Cancer.
Martin GA; Chen AH; Parikh K
Pharmacotherapy; 2017 Nov; 37(11):1406-1414. PubMed ID: 28895177
[TBL] [Abstract][Full Text] [Related]
19. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design.
Agarwal N; Azad A; Shore ND; Carles J; Fay AP; Dunshee C; Karsh LI; Paccagnella ML; Santo ND; Elmeliegy M; Lin X; Czibere A; Fizazi K
Future Oncol; 2022 Feb; 18(4):425-436. PubMed ID: 35080190
[TBL] [Abstract][Full Text] [Related]
20. Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer.
Chi KN; Rathkopf D; Smith MR; Efstathiou E; Attard G; Olmos D; Lee JY; Small EJ; Pereira de Santana Gomes AJ; Roubaud G; Saad M; Zurawski B; Sakalo V; Mason GE; Francis P; Wang G; Wu D; Diorio B; Lopez-Gitlitz A; Sandhu S;
J Clin Oncol; 2023 Jun; 41(18):3339-3351. PubMed ID: 36952634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
